Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
May 02, 2024 07:00 ET
|
Organogenesis Holdings Inc.
Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (p<0.0001) maintenance of function at six monthsTransformational opportunity for Organogenesis to...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
April 16, 2024 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
April 03, 2024 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
February 29, 2024 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
February 12, 2024 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
February 08, 2024 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
November 09, 2023 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
October 05, 2023 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS
September 28, 2023 09:15 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...